Announced details
Treatments for inflammatory diseases
The two companies entered into a license agreement for PDPS® in 2018. MSD is developing candidate compounds created using the Company's technology.
The name used by Merck & Co., Inc. when conducting business in countries and regions outside the United States and Canada. The location is listed as Rahway, N.J., U.S.A. Other details are Not disclosed.
The milestone fee is expected to be recognized as revenue in the fourth quarter of the fiscal year ending December 2026. It has been incorporated into the earnings forecast, and there is no change to the forecast.
The company does not address Contract Value / Offering price.
| Item | Details |
|---|---|
| Names of Products / Services Covered | PDPS® (Peptide Discovery Platform System) technology, Peptide development candidate compound |
| Counterparty | MSD (Merck & Co., Inc.) |
| Counterparty overview | The name used by Merck & Co., Inc. when conducting business in countries and regions outside the United States and Canada. The location is listed as Rahway, N.J., U.S.A. Other details are Not disclosed. |
| Relationship with the Company | The two companies entered into a license agreement for PDPS® in 2018. MSD is developing candidate compounds created using the Company's technology. |
| Contract Date | 2018 (PDPS® license agreement) |
| Launch date | 5 November 2026 (commencement of the Phase 1 clinical trial, actual) |
| Applicable area | Treatments for inflammatory diseases |
| Impact on Business Performance | The milestone fee is expected to be recognized as revenue in the fourth quarter of the fiscal year ending December 2026. It has been incorporated into the earnings forecast, and there is no change to the forecast. |
Items this document does not state (10)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Because MSD commenced a Phase 1 clinical trial of this compound. The trial is being conducted to evaluate safety, tolerability and pharmacokinetics in healthy volunteers, with the aim of developing the compound as a treatment for inflammatory diseases.